当前位置：药药网 / 药品 / 美国NDC复合药物数据库文件(本栏目更新到2026-3-31)
药品名称： 商品名称： 药品NDC： 报告期内： -格式:2020-5-3
NDC包装id： 市场分类： 活性成分： 持证企业：
 美国NDC复合药物数据库文件4843条(本栏目更新到2026-3-31)
药品名称(分析)
商品名
药品NDC
专利人(分析)
报告期内
活性成分
市场分类
规格(分析)
NDC包装id
031020 FINASTERIDE 0.1% / MINOXIDIL 5%
HUMAN COMPOUNDED DRUG
72934-4345
SKNV
2024-2
FINASTERIDE; MINOXIDIL
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
.1 g/100 mL; 5 g/100 mL
72934-4345-8
031030 MINOXIDIL 5% / PROGESTERONE 0.1% / TRETINOIN 0.025%
HUMAN COMPOUNDED DRUG
72934-4347
SKNV
2024-2
TRETINOIN; MINOXIDIL; PROGESTERONE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
.025 g/100 mL; 5 g/100 mL; .1 g/100 mL
72934-4347-8
091028 FLUOCINOLONE ACETONIDE 0.01% / NIACINAMIDE 4%
HUMAN COMPOUNDED DRUG
72934-2362
SKNV
2024-2
NIACINAMIDE; FLUOCINOLONE ACETONIDE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
4 g/100 mL; .01 g/100 mL
72934-2362-2
201026 LIDOCAINE 15% / PHENYLEPHRINE HCL 0.25% / PRILOCAINE 5%
HUMAN COMPOUNDED DRUG
72934-5403
SKNV
2024-2
LIDOCAINE; PRILOCAINE; PHENYLEPHRINE HYDROCHLORIDE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
15 g/100 mL; 5 g/100 mL; .25 g/100 mL
72934-5403-4
141069 HYDROQUINONE 8%//TRETINOIN 0.025%
HUMAN COMPOUNDED DRUG
72934-6392
SKNV
2024-2
HYDROQUINONE; TRETINOIN
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
8 g/100 mL; .025 g/100 mL
72934-6392-2
141017 HYDROCORTISONE 0.5% / HYDROQUINONE 6% / TRETINOIN 0.025%
HUMAN COMPOUNDED DRUG
72934-6376
SKNV
2024-2
HYDROCORTISONE; HYDROQUINONE; TRETINOIN
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
.5 g/100 mL; 6 g/100 mL; .025 g/100 mL
72934-6376-2
011557 DAPSONE 8.5% / NIACINAMIDE 2% / SPIRONOLACTONE 5%
HUMAN COMPOUNDED DRUG
72934-2325
SKNV
2024-1
SPIRONOLACTONE; DAPSONE; NIACINAMIDE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
5 g/100 mL; 8.5 g/100 mL; 2 g/100 mL
72934-2325-2
201070 BENZOCAINE 20% / LIDOCAINE 10% / TETRACAINE 10%
HUMAN COMPOUNDED DRUG
72934-2406
SKNV
2024-1
BENZOCAINE; LIDOCAINE; TETRACAINE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
20 g/100 mL; 10 g/100 mL; 10 g/100 mL
72934-2406-4
Phenylephrine Hydrochloride
HUMAN COMPOUNDED DRUG
65302-505
The Ritedose Corporation
2024-2
PHENYLEPHRINE HYDROCHLORIDE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
80 ug/1 mL
65302-505-10
Phenylephrine Hydrochloride
HUMAN COMPOUNDED DRUG
65302-506
The Ritedose Corporation
2024-2
PHENYLEPHRINE HYDROCHLORIDE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
100 ug/1 mL
65302-506-10
Neostigmine Methylsulfate
HUMAN COMPOUNDED DRUG
65302-501
The Ritedose Corporation
2024-2
NEOSTIGMINE METHYLSULFATE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
1 mg/1 mL
65302-501-05
Rocuronium Bromide
HUMAN COMPOUNDED DRUG
65302-510
The Ritedose Corporation
2024-2
ROCURONIUM BROMIDE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
10 mg/1 mL
65302-510-05
Lidocaine Hydrochloride 1%
HUMAN COMPOUNDED DRUG
65302-526
The Ritedose Corporation
2024-2
LIDOCAINE HYDROCHLORIDE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
10 mg/1 mL
65302-526-10
Vancomycin 1.5g added to 250mL of 0.9% Sodium Chloride
HUMAN COMPOUNDED DRUG
71170-184
Apollo Care, LLC
2024-2
VANCOMYCIN HYDROCHLORIDE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
6 mg/1 mL
71170-184-25
Vancomycin 1.5g added to 500mL of 0.9% Sodium Chloride
HUMAN COMPOUNDED DRUG
71170-185
Apollo Care, LLC
2024-2
VANCOMYCIN HYDROCHLORIDE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
3 mg/1 mL
71170-185-50
Ketamine 50 mg per 5 mL Syringe (10 mg/mL)
HUMAN COMPOUNDED DRUG
71170-050
Apollo Care, LLC
2024-2
KETAMINE HYDROCHLORIDE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
10 mg/1 mL
71170-050-05
Tacrolimus
HUMAN COMPOUNDED DRUG
73217-002
Stokes Healthcare
2024-2
TACROLIMUS
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
.3 mg/1 mL
73217-002-10
Tacrolimus
HUMAN COMPOUNDED DRUG
73217-005
Stokes Healthcare
2024-2
TACROLIMUS
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
10 mg/1 mL
73217-005-10
Albuterol Sulfate 0.5%
HUMAN COMPOUNDED DRUG
69374-330
Nephron Sterile Compounding Center, LLC
2024-2
ALBUTEROL
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
5 mg/1 mL
69374-330-05
Ropivacaine Hydrochloride 200 mg/100 mL
HUMAN COMPOUNDED DRUG
69374-987
Nephron Sterile Compounding Center, LLC
2024-2
ROPIVACAINE HYDROCHLORIDE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
2 mg/1 mL
69374-987-50
网站地图 - 网站开发 - 网站简介 - 会员服务 - 法律声明 - 联系我们 - 药品招商频道 - 药品信息排行 - 2018年版国家基本药物目录 - 意见反馈
免责声明：以上所展示的信息由企业自行提供，内容的真实性、准确性和合法性由发布企业负责，医药网对此不承担任何责任。
相关链接：医药研究数据| 医药资料| SDA药品评审中心| 中医网| 中药处方系统| 爱视立眼贴
专业提供药品信息、药品招商、药品代理、保健品招商、医药原料采购供应的中国药品信息网站平台
版权所有 © 2003-2028 盗冒必究　　客服热线：0575-83552251 / 13754370441  QQ客服：药品信息客服
浙ICP备16010490号-2 增值电信业务经营许可证：浙B2-20220931　互联网药品信息服务资格证书编号：(浙)-经营性2023-0215　浙公网安备:330683240604819103159
　医药代理商群１：药药网药品采购交流医药代理商群２：药药网药品采购交流2医药代理商群３：药药网药品采购交流3